Ryan Haumschild, PharmD, MS, MBA, CPEL

This episode, titled 'What It Takes to Make the Pathway: Clinical and Operational Criteria for Adding New Combinations in RRFL,' features Ryan Haumschild, PharmD, MS, MBA, CPEL discussing the following critical question:

In 'From Data to Practice: Interpreting inMIND Trial Results and the Role of Tafasitamab in RRFL,' Ryan Haumschild, PharmD, MS, MBA, CPEL delves into the following critical questions

Experts debate quadruplet myeloma therapy, MRD-guided de-escalation, and risk-adapted intensification—plus how payers may respond.

Explore how high-dose aflibercept and dual-pathway faricimab boost anti-VEGF durability, targeting VEGF-A and Ang-2 for better retinal outcomes.

Clinicians tailor treat-and-extend anti-VEGF care, using newer agents to control faster and stretch injections to 20 weeks, reducing burden.

Experts weigh quadruplet vs triplet myeloma therapy, tailoring to frailty and clots, and push early CAR-T/BCMA options for high-risk patients.

The panelists examined the significant progress made in frontline multiple myeloma treatment while emphasizing that true satisfaction will only come when more patients achieve a durable cure and can transition off maintenance therapy entirely, identifying MRD-guided treatment discontinuation as one of the most promising pathways toward that goal.

Experts unpack new myeloma regimens—quadruplet induction, dual maintenance, earlier smoldering therapy—plus real-world access and cost hurdles.

Welcome back to another AJMC Insights series. In this episode titled, 'Setting the Stage: Treatment Selection and Eligibility in Follicular Lymphoma,' Ryan Haumschild, PharmD, MS, MBA, CPEL led the conversation about the following questions: 1. What are the first-line treatment options in follicular lymphoma? 2. When are you considering a patient eligible for later lines of therapy?

Learn how next‑gen anti‑VEGF therapies rapidly control wet AMD, DME and vein occlusion, cutting injections and protecting vision.

Experts explain how longer-lasting anti-VEGF injections reduce treatment burden and improve real-world vision outcomes in AMD, DME, and RVO.

Explore how extended anti‑VEGF dosing cuts clinic burden, affects costs, and reveals key evidence gaps for AMD, DME, and RVO.

Explore how extended anti‑VEGF dosing impacts cost and care burden, plus key evidence gaps and next‑gen targets for AMD, DME and RVO.

Real-world retina data shows aflibercept 8 mg and faricimab extend anti-VEGF intervals and target Ang2/Tie2 for AMD and DME.

Real-world retina data shows how aflibercept 8 mg and faricimab extend anti-VEGF intervals, guiding treat-and-extend for AMD and DME.

Real-world anti‑VEGF outcomes lag trials as durability and missed injections matter; learn how evidence guides everyday wet AMD decisions.

How anti-VEGF injections reshape wet AMD, DME, and vein occlusion care, preserving vision—plus what real-world access barriers mean for patients.

How payers curb inappropriate ATTR-CM therapy use with better scans, prior auth, real-world outcomes, and telemedicine to speed access.

Experts weigh prior authorization, step therapy, and 12‑month coverage to balance access and cost for high‑value long‑term therapies.

Real-world evidence and claims data compare amyloidosis therapies, linking outcomes and symptom burden to total cost of care.

In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists explore the key clinical and economic considerations that drive therapy selection across the three available ATTR-CM treatments. Dr. Alexander opens by emphasizing shared decision-making as a foundational principle, noting that in the absence of head-to-head data, patient preferences carry significant weight alongside clinical judgment. He outlines several practical factors influencing treatment choice, including route of administration, as vutrisiran is a quarterly injection given in a healthcare setting, acoramidis is a twice-daily oral pill, and tafamidis is a once-daily oral pill, each presenting distinct advantages depending on patient circumstances such as pill burden or transportation access.

Long-term ATTR-CM trial data show durable benefits with early tafamidis or acoramidis, fewer deaths/hospitalizations, and manageable safety.

Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival.

Experts discuss the promising advancements in HER2-mutant lung cancer treatments, emphasizing the importance of molecular testing and clinical trials.

Emerging HER2-targeted therapies in lung cancer highlight the importance of real-world data and survival metrics for patient outcomes and treatment access.

Pharmacists play a vital role in oncology, enhancing patient care through medication management, education, and support for novel therapies.

This episode examines the barriers to accessing HER2-targeted therapies for non-small cell lung cancer (NSCLC) and strategies to overcome them. The discussion highlights the importance of aligning with payer requirements and clinical guidelines, such as those from NCCN, to facilitate insurance approval of recently FDA-approved HER2-targeted treatments.

Experts discuss the FDA's Accelerated Approval Program, emphasizing its role in providing earlier access to innovative cancer therapies for patients.